A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
Public ClinicalTrials.gov record NCT00000871. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To expand the available data regarding the safety and immunogenicity of 2 HIV-1 vaccine strategies: canarypox vector vCP205, or vCP205 with SF-2 rgp120. \[AS PER AMENDMENT 7/2/98: To obtain immunogenicity and safety data on gp120 subunits that may induce enhanced neutralizing antibody response to primary isolates of HIV-1 in the context of previous immunization with a canarypox vector expressing HIV antigens (vCP205). To evaluate cytotoxic T lymphocyte responses at 1 and 2 years after initial vaccination with vCP205 plus rgp120 SF-2 or vCP205 alone.\] In previous ALVAC vCP205/SF-2 rgp 120 studies, patients have developed antibodies that neutralize homologous laboratory strains; over 50% of patients have developed CD8+ cytotoxic T-lymphocyte responses to HIV env and gag epitopes at some point in the study. This Phase II study seeks to confirm these results among persons at lower or higher risk for HIV infection with a new lot of ALVAC vCP205, at a dose that is suitable for potential large-scale trials. \[AS PER AMENDMENT 7/2/98: Addition of AIDSVAX B/B or AIDSVAX B/E boosts starting at least 12 months after receiving rgp120 or ALVAC vaccines may induce enhanced neutralizing antibody response as deemed from prior studies and thus is planned as "follow-up" therapy.\]
Study identification
- NCT ID
- NCT00000871
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 420 participants
Conditions and interventions
Conditions
Interventions
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 Biological
- MN rgp120/HIV-1 and A244 rgp120/HIV-1 Biological
- ALVAC-HIV MN120TMG (vCP205) Biological
- rgp120/HIV-1 SF-2 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Dec 31, 1999
- Last update posted
- Nov 3, 2021
Ends 2000
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB AVEG | Birmingham | Alabama | 35294 | — |
| Public Health Enterprises Foundation, Inc. HIVNET | San Francisco | California | — | — |
| Denver Dept. of Health HIVNET | Denver | Colorado | — | — |
| Denver Public Health CRS | Denver | Colorado | — | — |
| Cook County Hospital HIVNET | Chicago | Illinois | 60612 | — |
| Univ. of Illinois at Chicago HIVNET | Chicago | Illinois | — | — |
| JHU AVEG | Baltimore | Maryland | 21205 | — |
| Fenway Community Health Center HIVNET | Boston | Massachusetts | 02115 | — |
| St. Louis Univ. School of Medicine AVEG | St Louis | Missouri | — | — |
| NY Blood Ctr. HIVNET | New York | New York | 10016 | — |
| NY Univ. Med. Ctr. HIVNET | New York | New York | 10016 | — |
| Univ. of Rochester AVEG | Rochester | New York | 14642 | — |
| Univ. of Pennsylvania HIVNET | Philadelphia | Pennsylvania | 19104 | — |
| Memorial Hosp. of Rhode Island HIVNET | Providence | Rhode Island | 02906 | — |
| The Miriam Hosp. HIVNET | Providence | Rhode Island | 02906 | — |
| Vanderbilt Univ. Hosp. AVEG | Nashville | Tennessee | 37232 | — |
| UW - Seattle AVEG | Seattle | Washington | — | — |
| Uw Hivnet | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00000871, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2021 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00000871 live on ClinicalTrials.gov.